Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
On WRAL at 11: Hot, hot weather continues on Monday during a WRAL Weather Alert. When showers and storms could cool us off
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
12.60
-0.01 (-0.08%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,695,792
Open
12.62
Bid (Size)
12.60 (7)
Ask (Size)
12.72 (1)
Prev. Close
12.61
Today's Range
12.60 - 12.71
52wk Range
12.57 - 16.39
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
June 22, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
June 21, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Performance
YTD
-12.13%
-12.13%
1 Month
-3.96%
-3.96%
3 Month
-10.95%
-10.95%
6 Month
-10.38%
-10.38%
1 Year
-20.10%
-20.10%
More News
Read More
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
June 21, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
June 18, 2024
Via
Benzinga
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
June 18, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 17, 2024
Via
Benzinga
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
June 17, 2024
Via
Benzinga
Japan Pharma Giant Takeda's Anti-Seizure Treatment Flunks In Two Late-Stage Studies
June 17, 2024
Via
Benzinga
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
June 17, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
June 15, 2024
Via
Talk Markets
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
June 14, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
June 11, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
7 F-Rated Stocks to Avoid at All Costs in June
June 06, 2024
Via
InvestorPlace
Blackstone Weighs Sale Of Japanese Pharma Firm Alinamin: Report
June 03, 2024
Via
Benzinga
Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
June 03, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
June 01, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
May 31, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
May 25, 2024
Via
Talk Markets
Week in Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal
May 19, 2024
Via
Talk Markets
Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement
May 15, 2024
Via
Benzinga
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
May 14, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
May 13, 2024
Via
Benzinga
Why Is AC Immune (ACIU) Stock Up 45% Today?
May 13, 2024
Via
InvestorPlace
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
May 13, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Catalyst's New CEO Has Big Ideas For The Small Biotech
May 10, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.